| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f21c1009c60308a64b8e7dc0bb989632 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate |
2012-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5f3186aabda571cc88e21228823e8d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_596d8e73c1061281db6daa756ac911b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0045d7dc37535ba06c06378b48c54a8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b6b408247dbf03b98f40326552bc72f |
| publicationDate |
2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2648189-T3 |
| titleOfInvention |
Methods to reduce adverse events caused by pharmaceutical preparations comprising proteins derived from plasma |
| abstract |
Method for reducing the activity of Factor XIa in a pharmaceutical preparation derived from a plasma fraction comprising antithrombin III, where the plasma fraction has been pre-absorbed to an anion exchange matrix (AEX) and the method comprises contacting the fraction of plasma with heparin, thus reducing the activity of Factor XIa per mL of the plasma fraction; where the heparin that comes into contact with the plasma fraction is covalently bound to a matrix, where the AEX matrix is an anion exchange membrane. |
| priorityDate |
2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |